HSPA5

Endoplasmic reticulum chaperone BiP · P11021 · HSPA5 on Sugi Atlas →

16,119 patent compounds predicted against HSPA5, 10,632 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL951554 SCHEMBL951554 0.56 5/20
SCHEMBL951556 SCHEMBL951556 0.56 5/20
SCHEMBL951557 SCHEMBL951557 0.56 5/20
SCHEMBL722580 SCHEMBL722580 0.77 3/20
SCHEMBL472569 SCHEMBL472569 0.72 3/20
SCHEMBL472571 SCHEMBL472571 0.72 3/20
SCHEMBL51173 SCHEMBL51173 0.67 3/20
SCHEMBL69620 SCHEMBL69620 0.58 3/20
SCHEMBL50622 SCHEMBL50622 0.54 3/20
SCHEMBL69852 SCHEMBL69852 0.53 3/20
SCHEMBL18352 SCHEMBL18352 0.50 3/20
SCHEMBL68255 SCHEMBL68255 0.50 3/20
SCHEMBL218957 SCHEMBL218957 0.50 3/20
SCHEMBL292109 SCHEMBL292109 0.50 3/20
SCHEMBL70468 SCHEMBL70468 0.46 3/20
SCHEMBL27533 SCHEMBL27533 1.00 2/20
SCHEMBL34162 SCHEMBL34162 1.00 2/20
SCHEMBL39149 SCHEMBL39149 0.96 2/20
Phosphoric Acid Phosphoric Acid (SCHEMBL636534) 0.89 2/20
SCHEMBL57329 SCHEMBL57329 0.82 2/20

Clinical trials — most relevant to HSPA5 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Effects of Liraglutide on ER Stress in Obese Patients With Type 2 Diabetes PHASE4UNKNOWN
Glycerol-Phenylbutyrate Treatment in Children With MCT Mutation (Allan-Herndon- Dudley Syndrome) PHASE2/PHASE3UNKNOWN
Targeting Endoplasmic Reticulum Stress in Human Hypertension PHASE1/PHASE2RECRUITING
Ambroxol Therapy for Patients With Type 1 Gaucher Disease and Suboptimal Response to Enzyme Replacement Therapy PHASE2COMPLETED
Evaluation of the Possible Safety and Efficacy of Dapagliflozin in the Prophylaxis of Doxorubicin-Induced Cardiotoxicity PHASE2RECRUITING
Megestrol Acetate or Levonorgestrel-Releasing Intrauterine System in Treating Patients With Atypical Endometrial Hyperplasia or Endometrial Cancer PHASE2WITHDRAWN
Fulvestrant With or Without Bortezomib in Patients With Inoperable Locally Advanced or Metastatic Estrogen Receptor Positive Breast Cancer PHASE2COMPLETED
Pembrolizumab Plus Enfortumab Vedotin in Collecting Duct and Renal Medullary Carcinoma PHASE2RECRUITING
Safety and Efficacy of DA-9805 for Parkinson's Disease PHASE2COMPLETED
Vorinostat and Bortezomib in Treating Young Patients With Refractory or Recurrent Solid Tumors, Including Central Nervous System Tumors and Lymphoma PHASE1COMPLETED
A Phase I Study of Pyrimethamine in Patients With GM2 Gangliosidosis PHASE1WITHDRAWN
Study of Oral CNF2024 (BIIB021) in Advanced Solid Tumors PHASE1COMPLETED
Safety and Pharmacology of SNX-5422 Plus Carboplatin and Paclitaxel in Subjects With Solid Tumors PHASE1COMPLETED
PBA Use for Treatment of ATF6-/- Patients EARLY_PHASE1SUSPENDED
Quantification of GADD34 Expression in RA nanCOMPLETED
Establishment of Human Cellular Disease Models for Wilson Disease nanCOMPLETED
Wolfram Syndrome and WFS1-related Disorders International Registry and Clinical Study nanRECRUITING
Targeting ER-Golgi Homeostasis in an Advantageous Therapeutic Strategy in Lung Cancer nanUNKNOWN
Effect of Protein on Endoplasmic Reticulum Stress nanNOT_YET_RECRUITING
LncRNA Nicotinamide Nucleotide Transhydrogenase-Antisense RNA1 NNT-AS1 in CRC nanCOMPLETED
Hereditary Spastic Paraplegia Genomic Sequencing Initiative (HSPseq) nanRECRUITING
Endoplasmic Reticulum Stress and Resistance to Treatments in Ph-negative Myeloproliferative Neoplasms nanCOMPLETED
Mitoquines in COPD nanUNKNOWN
MERC Proteins in Saliva and GCF in Periodontal Disease (ELISA Study) nanCOMPLETED
Efficacy and Safety of Deep Cervical Lymph Node-vein Bypass Surgery in ALS Amyotrophic Lateral Sclerosis nanNOT_YET_RECRUITING
Calorie Restriction and Brain Function in Mild Cognitive Impairment nanCOMPLETED
Fatty Acids Lipidome and Oxidative Stress in Liver Transplantation nanUNKNOWN
Tracking Neurodegeneration in Early Wolfram Syndrome nanCOMPLETED
Exercise on Expression of Heat Shock Protein 70 in Arterial Risk nanCOMPLETED
Reduced Ventilator-Free Days and Bacterial Colonization of Sub-Glottic Secretions nanWITHDRAWN

Related proteins — ESM-2 sequence neighbours (a HSPA5 binder may also engage these)

ProteinNameSimilarity
P20029 1.000 P20029 →
Q5R4P0 1.000 Q5R4P0 →
Q90593 1.000 Q90593 →
Q0VCX2 1.000 Q0VCX2 →
Q3S4T7 1.000 Q3S4T7 →
P06761 1.000 P06761 →
P07823 1.000 P07823 →
G3I8R9 1.000 G3I8R9 →
Q24895 1.000 Q24895 →
Q9FSY7 1.000 Q9FSY7 →
P29844 1.000 P29844 →
P20163 1.000 P20163 →
Q24798 1.000 Q24798 →
Q03684 1.000 Q03684 →
Q39043 1.000 Q39043 →
Q6Z7B0 1.000 Q6Z7B0 →
P49118 1.000 P49118 →
P19208 1.000 P19208 →
P78695 1.000 P78695 →
Q03685 1.000 Q03685 →
Q91883 1.000 Q91883 →
P24067 1.000 P24067 →
Q9LKR3 1.000 Q9LKR3 →
P27420 1.000 P27420 →
Q42434 1.000 Q42434 →
O24581 1.000 O24581 →
Q05866 0.998 Q05866 →
P87047 0.998 P87047 →
Q71U34 0.997 Q71U34 →
A2Q0Z1 0.997 A2Q0Z1 →